Search results
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 4 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma ...
...BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE...
Morningstar· 5 days agoFood and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative ...
Rituximab Tied to Increased Infection Risk in RRMS
Medscape· 6 days agoThe B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.
CAR-T therapy achieves lupus remission breakthrough
BioPharma-Reporter· 20 hours agoThis is the first trial to date to show safe elimination of all autoantibodies in patients with systemic lupus erythematosus (SLE) and lupus nephritis...
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
Study shows treatment for autoimmune disorder shifts balance of immune cell types
Medical Xpress· 14 hours agoAutoimmune diseases cannot currently be cured, only treated, and this is also true for neuromyelitis optica spectrum disorder, which affects the central nervous system. A Kobe University study ...
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
Morningstar· 5 days agoThe biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-< ...
Nurix Therapeutics (NASDAQ:NRIX) Price Target Increased to $26.00 by Analysts at HC Wainwright
ETF DAILY NEWS· 6 hours agoNurix Therapeutics (NASDAQ:NRIX – Free Report) had its price objective increased by HC Wainwright from $19.00 to $26.00 in a research report released on Tuesday, Benzinga reports. Stephens initiated ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 7 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.4% on Analyst Upgrade
ETF DAILY NEWS· 7 hours agoNurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) shares were up 4.4% on Tuesday after HC Wainwright raised their price target on the stock from $19.00 to $26.00. HC Wainwright currently ...